SYGMA 2
Symbicort Given As Needed in Mild Asthma 2
Patient / Population Intervention / Exposure Comparison Outcome
In 4,215 patients with mild asthma, PRN budesonide-formoterol was non-inferior for severe exacerbations compared with daily maintenance budesonide plus PRN terbutaline.
N
4,215
Design
Multicentre RCT
Endpoint
Annual rate of severe exacerbations
Relevance
2
ResultRR 0.97 (non-inferior) with ~25% of the ICS dose.
Bateman ED, et al. N Engl J Med. 2018;378(20):1877-1887. 10.1056/NEJMoa1715275
Discussion & critique
Cemented PRN ICS-formoterol as an alternative to daily maintenance ICS in mild asthma.